RETA GLP-3Explore study findings
What retatrutide blood samples reveal about changing fuel use
1 numbered sourceSource years 2026
Peptides are short chains of amino acids linked by peptide bonds. They can engage receptors that help direct the body’s handling of different fuels. Retatrutide is an investigational peptide that activates the GIP, GLP-1 and glucagon receptors. The “GLP-3” label refers to the catalog entry. In a 2026 analysis, investigators used stored blood samples from two randomized phase 2 trials to look for patterns in small molecules associated with fuel metabolism. [1]
The researchers studied fasting samples from participants with obesity with or without type 2 diabetes. They measured metabolites, which include small molecules produced or used during chemical reactions, and a range of lipid molecules. Several molecules involved in the handling of fatty acids changed together in retatrutide groups. The researchers also saw changes in some molecules associated with insulin resistance. Examining many compounds allowed them to look for related patterns rather than relying on a single blood marker. [1]
The paper used a statistical method called mediation analysis to examine how much of the observed weight response might be associated with a group of metabolic changes. The estimates differed between the two populations. This kind of analysis can test whether a set of observations is consistent with a proposed pathway. The underlying treatment assignment was randomized, but the changes in the molecules themselves were not assigned. As a result, the model’s estimates depend on assumptions about how the markers and outcomes are related. [1]
The blood samples provide information about molecules circulating at the times they were collected. They do not measure every reaction occurring inside fat, muscle or liver cells. The analysis was also exploratory and performed using existing trial data. It offers a set of hypotheses for future work, including which changes might accompany weight reduction and whether those relationships differ in people with type 2 diabetes. [1]
These observations are separate from the result of a trial designed to measure a clinical outcome such as kidney failure or cardiovascular events. The lipid and metabolite patterns can help researchers choose which mechanisms to examine more directly. They should be interpreted at the level of what the investigators measured, including the two study populations and the fact that the outcomes were analyzed after the original trials. [1]
Sources
Original works cited in this article. Links open the external record in a new tab.
